Fund shareholders of Collegium Pharmaceutical Inc
ISIN US19459J1043 · United States · LEI 54930049FXZMTLW8D496
- Fund shareholders
- 302
- Of which ETFs
- 88 214 other funds
- Value held
- ≈ 628.1M $ 628.1M $ · 27.6K €
- Share of capital
- 55.8 % of 32.6M shares on Jul 31, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| Russell 2000(R) 1.5x Strategy Fund Rydex Variable Trust | 8 | 264.6 $ | 0.01 % | 0.00 % | as of Mar 31, 2026 ↗ |
| GESTION BOUTIQUE VII, FI GESTION BOUTIQUE VII / SYSTEMATIC VALUE INVESTING US MARKETS ANDBANK WEALTH MANAGEMENT, SGIIC, S.A.U. | 27.6K € | 2.83 % | as of Dec 31, 2025 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| Abacus FCF Small Cap Leaders ETF Abacus FCF ETF Trust | 4.39 % | as of Apr 30, 2026 ↗ |
| Third Avenue Small-Cap Value Fund Third Avenue Trust | 3.06 % | as of Apr 30, 2026 ↗ |
| GESTION BOUTIQUE VII, FI GESTION BOUTIQUE VII / SYSTEMATIC VALUE INVESTING US MARKETS ANDBANK WEALTH MANAGEMENT, SGIIC, S.A.U. | 2.83 % | as of Dec 31, 2025 ↗ |
| Invesco Pharmaceuticals ETF Invesco Exchange-Traded Fund Trust | 2.19 % | as of Apr 30, 2026 ↗ |
| Invesco Biotechnology & Genome ETF Invesco Exchange-Traded Fund Trust | 2.12 % | as of Apr 30, 2026 ↗ |
| F/m Emerald Life Sciences Innovation ETF RBB Fund, Inc. | 2.06 % | as of Feb 28, 2026 ↗ |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF SPDR SERIES TRUST | 1.78 % | as of Mar 31, 2026 ↗ |
| PROFUND VP PHARMACEUTICALS ProFunds | 1.71 % | as of Mar 31, 2026 ↗ |
| Eventide Gilead Fund MUTUAL FUND SERIES TRUST | 1.66 % | as of Mar 31, 2026 ↗ |
| BALLAST SMALL/MID CAP ETF Unified Series Trust | 1.63 % | as of Mar 31, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Shareholders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q2 | 301 | +17 | 18,161,305 | +5.0 % |
| 2026Q1 | 284 | +2 | 17,302,413 | -2.0 % |
| 2025Q4 | 282 | +10 | 17,661,275 | -4.7 % |
| 2025Q3 | 272 | 0 | 18,525,464 | -0.3 % |
| 2025Q2 | 272 | +1 | 18,575,296 | -9.0 % |
| 2025Q1 | 271 | -21 | 20,416,638 | +4.2 % |
| 2024Q4 | 292 | +18 | 19,597,364 | -13.1 % |
| 2024Q3 | 274 | +4 | 22,561,799 | +4.8 % |
| 2024Q2 | 270 | +25 | 21,535,377 | +7.9 % |
| 2024Q1 | 245 | -4 | 19,949,448 | +5.5 % |
| 2023Q4 | 249 | 18,913,637 |
Institutional managers
258 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| BlackRock, Inc. | 5,134,027 | 169.8M $ | as of Mar 31, 2026 |
| JANUS HENDERSON GROUP PLC | 1,825,651 | 60.4M $ | as of Mar 31, 2026 |
| Invesco Ltd. | 1,591,909 | 52.6M $ | as of Mar 31, 2026 |
| FULLER & THALER ASSET MANAGEMENT, INC. | 1,499,584 | 49.6M $ | as of Mar 31, 2026 |
| RENAISSANCE TECHNOLOGIES LLC | 1,469,449 | 48.6M $ | as of Mar 31, 2026 |
| STATE STREET CORP | 1,424,544 | 47.1M $ | as of Mar 31, 2026 |
| EVENTIDE ASSET MANAGEMENT, LLC | 1,424,282 | 47.1M $ | as of Mar 31, 2026 |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 1,365,932 | 45.2M $ | as of Mar 31, 2026 |
| PRINCIPAL FINANCIAL GROUP INC | 1,295,028 | 42.8M $ | as of Mar 31, 2026 |
| Rubric Capital Management LP | 1,279,611 | 42.3M $ | as of Mar 31, 2026 |
| DIMENSIONAL FUND ADVISORS LP | 833,192 | 27.6M $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 819,440 | 27.1M $ | as of Mar 31, 2026 |
| MARSHALL WACE, LLP | 748,812 | 24.8M $ | as of Mar 31, 2026 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 703,528 | 23.3M $ | as of Mar 31, 2026 |
| VICTORY CAPITAL MANAGEMENT INC | 625,304 | 20.7M $ | as of Mar 31, 2026 |
| Qube Research & Technologies Ltd | 621,935 | 20.6M $ | as of Mar 31, 2026 |
| TWO SIGMA INVESTMENTS, LP | 590,116 | 19.5M $ | as of Mar 31, 2026 |
| GOLDMAN SACHS GROUP INC | 575,141 | 19M $ | as of Mar 31, 2026 |
| D. E. Shaw & Co., Inc. | 530,698 | 17.6M $ | as of Mar 31, 2026 |
| MORGAN STANLEY | 515,179 | 17M $ | as of Mar 31, 2026 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 495,027 | 16.4M $ | as of Mar 31, 2026 |
| AMERICAN CENTURY COMPANIES INC | 460,744 | 15.2M $ | as of Mar 31, 2026 |
| EMERALD ADVISERS, LLC | 402,752 | 13.3M $ | as of Mar 31, 2026 |
| LOOMIS SAYLES & CO L P | 375,666 | 12.4M $ | as of Mar 31, 2026 |
| NORTHERN TRUST CORP | 361,889 | 12M $ | as of Mar 31, 2026 |
Declared shareholders of Collegium Pharmaceutical Inc
There are 5 beneficial ownership filings. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 5.80 % | 1,825,651 | as of Mar 31, 2026 · SCHEDULE 13G |
| Invesco Ltd. | 5.00 % | 1,591,909 | as of Mar 31, 2026 · SCHEDULE 13G |
| Integrated Core Strategies (US) LLC and 3 others | 4.70 % | 1,519,500 | as of May 7, 2026 · SCHEDULE 13G |
| Renaissance Technologies LLC and 1 other | 4.53 % | 1,469,449 | as of Jan 8, 2026 · SCHEDULE 13G |
| Eventide Asset Management, LLC and 2 others | 4.50 % | 1,424,282 | as of Mar 31, 2026 · SCHEDULE 13G |
Funds holding the debt of Collegium Pharmaceutical Inc
10 funds declare 10 bond lines of this company. The amount is the one the fund files. It is not a share of the debt, because no regulator publishes the amount outstanding in open access.
| Fund | Bond lines | Value | |
|---|---|---|---|
| Miller Market Neutral Income Fund | 1 | 4.1M $ | as of Apr 30, 2026 |
| American Beacon SSI Alternative Income Fund | 1 | 4M $ | as of Mar 31, 2026 |
| Fidelity Convertible Securities Fund | 1 | 2.2M $ | as of Feb 28, 2026 |
| Strategic Alternatives Fund | 1 | 987.2K $ | as of Mar 31, 2026 |
| Morningstar Alternatives Fund | 1 | 955.1K $ | as of Apr 30, 2026 |
| Fidelity Strategic Dividend and Income Fund | 1 | 922.3K $ | as of Feb 28, 2026 |
| Miller Convertible Total Return ETF | 1 | 148.4K $ | as of Apr 30, 2026 |
| JNL Multi-Manager Alternative Fund | 1 | 91.1K $ | as of Mar 31, 2026 |
| Franklin Alternative Strategies Fund | 1 | 46.8K $ | as of Feb 27, 2026 |
| PACE Alternative Strategies Investments | 1 | 34K $ | as of Apr 30, 2026 |
Cite this page
Titelia. "Fund shareholders of Collegium Pharmaceutical Inc". https://titelia.com/en/stocks/collegium-pharmaceutical-inc-US19459J1043